Clinical

Patients with myasthenia gravis had a more consistent clinical response and fewer deteriorations when using add-on therapy early.

Investigators in China touted durable responses seen in a phase 2 study of the CAR T-cell therapy relma-cel, which has a similar mechanism of action as liso-cel. At present, there are no approved CAR T-cell therapies for relapsed/refractory mantle cell lymphoma in China.

A new review highlights the potential to develop ways to better anticipate and treat Richter transformation in patients with chronic lymphocytic leukemia.

Genmab’s epcoritamab (Epkinly) streamlines bispecific antibody workflows for DLBCL and follicular lymphoma, cutting chair time, waste, and costs.

In a cohort of veterans with steatotic liver disease, patients with metabolic- and alcohol-associated liver disease had the lowest incidence of cirrhosis.

Meta-analysis links obstructive sleep apnea to early kidney injury markers, especially in severe OSA and hypertension, highlighting need for renal monitoring.

Noel T. Brewer, PhD, former ACIP member, warns that the CDC's reduction from 17 to 11 recommended immunizations lacks transparency, which may lower uptake.

In Advocacy Strategies and the Expanding Role of Novel Therapies in IgA Nephropathy, our panel delves into the following critical questions: What strategies can clinicians use to advocate for access or navigate step edits? How might real-world data and ongoing registries (like RaDaR) support broader adoption and payer confidence?

In this episode, Overcoming Access Barriers and Step-Edit Challenges in IgA Nephropathy Care, the panelists explore the following questions: What barriers exist to real-world use, particularly around payer policies or access? Many plans require a systemic steroid step-edit; why might this be inappropriate for IgAN?

Enfortumab vedotin plus pembrolizumab boosts survival and pCR in muscle-invasive bladder cancer, according to EV-304 trial data.

Azathioprine use in organ transplant recipients increases the risk of squamous cell, but not basal cell, carcinoma.

Experts examine evolving long COVID definitions, risk factors, diagnosis challenges, vaccine impact, and workforce effects.

This approval was based on data from the Beamion LUNG-1 trial.

Emerging CRC diagnostic tools along with better public awareness could help reverse rising deaths in younger adults, says Jordan Karlitz, MD.

Orforglipron achieved greater A1C reduction and weight loss than oral semaglutide, highlighting its potential as a needle-free option for type 2 diabetes.

Nurse understaffing linked to higher in-hospital mortality, 30-day readmissions, and longer stays.

Experts weigh lung cancer perioperative immunotherapy trials, debating adjuvant nivolumab, ctDNA guidance, and chemo choices versus pembrolizumab data.

Experts discuss the promising advancements in HER2-mutant lung cancer treatments, emphasizing the importance of molecular testing and clinical trials.

How EGFR, ALK and PD-L1 biomarker results shape neoadjuvant lung cancer therapy—and what CheckMate-816 means for survival.

Data from the phase 3 BREAKWATER trial supported full FDA approval of the encorafenib combination for metastatic CRC with a BRAF V600E mutation, demonstrating significant survival gains.

The increase in CRC-related mortality in younger adults is driven by screening delays and advanced-stage diagnoses, according to Jordan Karlitz, MD.

FDA draft guidance outlines a new pathway to speed up approval of individualized genome and RNA therapies for rare diseases when RCTs are not feasible.

FDA approves 4-dose KwikPen for tirzepatide (Zepbound; Eli Lilly), offering a full month of weight management treatment in 1 device.

A new study finds higher radiation to key brain stem cell regions in NSCLC brain metastases tied to shorter survival.

Many eligible patients miss lung cancer screening due to low awareness and systemic barriers, putting underserved groups at higher risk for late-stage disease.